Stiolto Respimat

Chronic Obstructive Pulmonary Disease
Treatment
20 Active Studies for Stiolto Respimat

What is Stiolto Respimat

OlodaterolThe Generic name of this drug
Treatment SummaryTiotropium is a medication used to treat chronic obstructive pulmonary disease (COPD) and asthma. It works by relaxing the muscles in the airways, making it easier to breathe. This drug is more specific for the muscarinic receptors found in the lungs than other similar drugs. It was approved by the FDA in 2004.
Striverdi Respimatis the brand name
image of different drug pills on a surface
Stiolto Respimat Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Striverdi Respimat
Olodaterol
2014
2

Effectiveness

How Stiolto Respimat Affects PatientsTiotropium is a medication that helps to open up the airways in the lungs, causing easier breathing. This effect can last for over a day, and even if too much of the drug is taken, serious side effects are rare.
How Stiolto Respimat works in the bodyTiotropium relaxes the muscles in the lungs, allowing them to open up and improve breathing. This effect is caused by the drug blocking certain receptors in the smooth muscle of the lungs.

When to interrupt dosage

The recommended dosage of Stiolto Respimat is contingent upon the diagnosed condition, including Chronic Bronchitis, Bronchoconstriction and Acute Bronchitis. The measure of dosage is also dependent on the technique of delivery (e.g. Respiratory (inhalation) or Spray, metered) portrayed in the table beneath.
Condition
Dosage
Administration
Chronic Obstructive Pulmonary Disease
0.0025 mg, , 0.002736 mg, 0.0025 mg/pump actuation
, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution, Spray, metered, Spray, metered - Respiratory (inhalation)

Warnings

Stiolto Respimat Contraindications
Condition
Risk Level
Notes
Asthma
Do Not Combine
There are 20 known major drug interactions with Stiolto Respimat.
Common Stiolto Respimat Drug Interactions
Drug Name
Risk Level
Description
Amiodarone
Major
The metabolism of Amiodarone can be decreased when combined with Olodaterol.
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Olodaterol.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Olodaterol.
Enasidenib
Major
The metabolism of Enasidenib can be decreased when combined with Olodaterol.
Erlotinib
Major
The metabolism of Erlotinib can be decreased when combined with Olodaterol.
Stiolto Respimat Toxicity & Overdose RiskTaking too much tiotropium can cause confusion, shaking, stomach pain, and constipation. However, doses up to 282µg have not been associated with serious anticholinergic side effects in clinical trials. If someone overdoses on tiotropium, treatment should focus on relieving symptoms.
image of a doctor in a lab doing drug, clinical research

Stiolto Respimat Novel Uses: Which Conditions Have a Clinical Trial Featuring Stiolto Respimat?

280 active clinical trials are being conducted to explore the potential of Stiolto Respimat in mitigating Asthma, Bronchoconstriction and Chronic Obstructive Pulmonary Disease (COPD).
Condition
Clinical Trials
Trial Phases
Chronic Obstructive Pulmonary Disease
77 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Stiolto Respimat Reviews: What are patients saying about Stiolto Respimat?

5Patient Review
2/18/2018
Stiolto Respimat for Bronchospasm Prevention with COPD
This medication has made a significant difference in my breathing. I'm glad I was prescribed it sooner rather than later.
5Patient Review
10/12/2022
Stiolto Respimat for Prevention of Bronchospasm with Chronic Bronchitis
I cannot say enough good things about this inhaler. It has truly been a lifesaver for me.
4.3Patient Review
12/4/2021
Stiolto Respimat for Bronchospasm Prevention with COPD
This treatment really helped me improve my breathing, but I hate the inhaler itself. I've had two now that have skipped doses or shorted me on dosages. Sometimes it sprays with such force you can't help but cough. I had no idea how bad my breathing was until I started this medication, and now I feel 10 years younger.As for the person who said it was too expensive even with an insurance plan, I say find another plan. I pay $9.20 for 3 months worth of the stuff.
4.3Patient Review
7/11/2020
Stiolto Respimat for Prevention of Bronchospasms with Emphysema
While it does help with my GERD, I have to be careful not to use too much or else it will cause an irregular heartbeat and high blood pressure. But at least I can breathe!
4.3Patient Review
5/17/2018
Stiolto Respimat for Bronchospasm Prevention with COPD
I had no idea how much better my breathing could be until I started taking this medication. So glad I found it!
3.7Patient Review
10/1/2020
Stiolto Respimat for Prevention of Bronchospasm with Chronic Bronchitis
My shortness of breath has improved after using this medication, but I seem to have common cold-like symptoms such as hayfever or seasonal allergies. However, the cost would be over $400 per month on Medicare with a drug supplement plan.
3.7Patient Review
4/6/2019
Stiolto Respimat for Bronchospasm Prevention with COPD
I think the new application method is better, but I don't feel it works as well as my old combo of SPIRIVA and SYMBICORT. My breathing isn't as good under strain since switching.
3.3Patient Review
1/1/2021
Stiolto Respimat for Bronchospasm Prevention with COPD
I was really disappointed that this inhaler didn't last a full month. There's a little knob inside the chamber that makes it stop working when it's out, but if you remove that knob, the inhaler will actually last almost two months. I think it's wrong of the manufacturer to do that. Hope this saves someone else some money.
1.3Patient Review
2/9/2022
Stiolto Respimat for Bronchospasm Prevention with COPD
This treatment was unfortunately very negative and scary for me. I saw no improvement in my breathing, and it actually got worse. Additionally, I developed pain in my right side torso that felt similar to cracked or broken ribs. On top of that, my salivary glands started swelling (on day 9) and I was urinating excessively at night. Finally, I developed a rash with blisters on my central abdomen.
1.3Patient Review
1/25/2022
Stiolto Respimat for Bronchospasm Prevention with COPD
This treatment was negative and scary for me. I saw no improvement in my breathing, and it even got worse. I also started experiencing pain in my torso on the right side, which felt like cracked or broken ribs. Additionally, my salivary glands started swelling on day 9, making it difficult to swallow. And finally, I was waking up several times each night to urinate and became constipated.
1.3Patient Review
5/23/2022
Stiolto Respimat for Bronchospasm Prevention with COPD
The side effects of this medication are horrendous. I experienced muscle weakness, back pain, insomnia, eye pain, and loss of appetite--and saw no improvement in my breathing whatsoever. Do not bother taking this; it's not worth the suffering.
1.3Patient Review
3/29/2020
Stiolto Respimat for Bronchospasm Prevention with COPD
Stiolto has not helped me with my breathing at all. I still feel tightness in my chest and have experienced some chest pain. Additionally, the delivery system is really terrible. I never know if the mist came out or if I breathed it in properly. Overall, I do not recommend this treatment option.
1.3Patient Review
1/6/2022
Stiolto Respimat for Bronchospasm Prevention with COPD
This had no effect on my copd whatsoever. I had to go back to advair. At least I can breathe with advair.
1Patient Review
10/24/2020
Stiolto Respimat for Bronchospasm Prevention with COPD
I've been using this medication as prescribed, but I haven't seen or felt any benefits from taking it.
1Patient Review
3/17/2021
Stiolto Respimat for Bronchospasm Prevention with COPD
I had an awful reaction to this treatment, developing a rash and chest pains. I stopped using it after only two days. Do not recommend.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about stiolto respimat

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Stiolto Respimat used for?

"Stiolto Respimat is a prescription medicine that is used to control symptoms in adults who have COPD. It is taken as two puffs once each day."

Answered by AI

Is Stiolto Respimat a steroid?

"STIOLTO RESPIMAT is a maintenance medication that does not contain steroids and is designed to be inhaled. For many people with chronic obstructive pulmonary disease (COPD), just breathing can be an everyday struggle."

Answered by AI

What are the side effects of Stiolto Respimat inhaler?

"urinary retention

Sinus irritation and a sore throat (nasopharyngitis) are common symptoms, as is a cough. Other symptoms include back pain, dehydration, dizziness, insomnia, glaucoma, and blurred vision. Urinary retention is another possible symptom."

Answered by AI

What kind of inhaler is Stiolto Respimat?

"STIOLTO RESPIMAT is a long-term prescription medication used to control symptoms in adults with COPD. The recommended dosage is 2 puffs 1 time per day."

Answered by AI

Clinical Trials for Stiolto Respimat

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+
All Sexes
Stanford, CA
Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.
Waitlist Available
Has No Placebo
Stanford UniversityJeff Swigris, DO, MSMinnesota Health Solutions
Have you considered Stiolto Respimat clinical trials? We made a collection of clinical trials featuring Stiolto Respimat, we think they might fit your search criteria.Go to Trials
Image of The University of Tennessee Graduate School of Medicine in Knoxville, United States.

Nebulizer vs Inhaler for COPD

18+
All Sexes
Knoxville, TN
The purpose of this study is to compare the effectiveness of inhaled bronchodilators delivered via nebulizers vs. dry powder inhalers (DPIs) in symptomatic participants with Chronic Obstructive Pulmonary Disease (COPD) who have airflow obstruction (FEV1/FVC ≤ 70%) and show significant air trapping (RV ≥ 120% of predicted). The investigators hypothesize that, in patients with symptomatic COPD, therapy with a long-acting anti muscarinic agent/long-acting beta agonist (LAMA/LABA) combination administered by nebulizer will improve hyperinflation (increase in inspiratory capacity and reduction in residual volume) and reduce symptoms related to COPD to a greater extent than LAMA/LABA therapy given by a DPI. The study aims to demonstrate the following: 1. Compare the values of inspiratory capacity (IC) and residual volume (RV) in patients receiving LAMA/LABA by DPI with those receiving LAMA/LABA by nebulizer 2. Compare patient reported outcomes (COPD Assessment Test (CAT score), Baseline/Transition Dyspnea Index (BDI/TDI) and the St. George Respiratory Questionnaire (SGRQ) in symptomatic patients with COPD receiving LAMA/LABA by DPI with those receiving LAMA/LABA by nebulizer
Phase 4
Recruiting
The University of Tennessee Graduate School of MedicineTheravance Biopharma
Have you considered Stiolto Respimat clinical trials? We made a collection of clinical trials featuring Stiolto Respimat, we think they might fit your search criteria.Go to Trials
Image of University of Massachusetts Chan Medical School in Worcester, United States.

Paramedic Evaluation for Chronic Obstructive Pulmonary Disease

18+
All Sexes
Worcester, MA
Chronic Obstructive Pulmonary Disease (COPD) is a serious lung condition that affects millions of people in the United States. Each year, it leads to about 150,000 deaths, nearly 900,000 emergency room visits, and 700,000 hospital stays. When COPD symptoms suddenly get worse-called an exacerbation-it can seriously harm a person's quality of life and often requires emergency care. Treating these flare-ups early can help prevent hospital visits, but right now, there aren't many good ways to make sure people get care quickly. Mobile Integrated Health (MIH) programs send specially trained paramedics, guided remotely by doctors, to care for patients in their homes. This approach could help people with COPD get faster, more effective care without needing to go to the hospital. In this project, the investigators are testing a new program called PEACE (Paramedic Evaluation for Acute COPD Exacerbation). The PEACE program sends community paramedics to patients' homes-when needed and in partnership with their regular doctors-to manage worsening COPD symptoms early. The study team will adapt the PEACE program to meet the needs of adults living at home with moderate to severe COPD, gather feedback from patients and healthcare providers, and run a small pilot study to see if the program is practical and helpful.
Recruiting
Has No Placebo
University of Massachusetts Chan Medical SchoolLaurel O'Connor, MD, MSc
Image of Cleveland Clinic Foundation in Cleveland, United States.

Multidisciplinary Clinic Evaluation for Sarcopenia Due to COPD

18+
All Sexes
Cleveland, OH
Sarcopenia, or skeletal muscle loss, impacts up to 40% of COPD patients and is a major cause for morbidity and mortality. Despite the high clinical significance of sarcopenia in COPD, the diagnosis remains elusive because accurate measures of skeletal muscle are not tested during routine clinical care. The goal is to use evidence-based strategies to diagnose and treat sarcopenia due to COPD. The multidisciplinary team includes a pulmonologist, pharmacist, COPD nurse, and COPD coordinator. The investigators anticipate that the approach will improve clinical outcomes for COPD patients with sarcopenia as compared to standard of care visits in ambulatory COPD clinics. The investigators will determine if the approach improves skeletal muscle mass and function, and also improves clinical outcomes related to frequency of hospitalization or ED (Emergency Department) visits, COPD exacerbations, and mortality.
Recruiting
Has No Placebo
Cleveland Clinic FoundationAmy Attaway, MD
Image of Duke Asthma Allergy and Airway Center in Durham, United States.

Inhaled Treprostinil for Chronic Obstructive Pulmonary Disease

18+
All Sexes
Durham, NC
The goal of this clinical trial is to evaluate whether inhaled Treprostinil (Tyvaso) can improve oxygen delivery and blood flow in the lungs in adults (age ≥40) with chronic obstructive pulmonary disease (COPD) and hypoxemia who have less severe reduction in lung blood volume (diffusing capacity of the lungs for carbon monoxide \[DLCO\] ≥45%). The main questions it aims to answer are: 1. Does inhaled Treprostinil increase pulmonary capillary blood volume in ventilated lung regions, as measured by hyperpolarized xenon-129 magnetic resonance imaging (HP129Xe MRI)? 2. Does inhaled Treprostinil improve oxygen delivery (measured as red blood cell \[RBC\] chemical shift) and maintain or only slightly change pulmonary vascular resistance (measured by RBC oscillation amplitude)? 3. Can pre-treatment MRI parameters (RBC transfer and RBC oscillation amplitude) predict who will respond to inhaled Treprostinil? Participants will: * Use the Tyvaso nebulizer (inhaled Treprostinil) 4 times daily for 4 weeks, starting at 3 breaths per session and increasing to a maximum of 6 breaths per session as tolerated. * Undergo HP129Xe MRI before and after treatment to assess regional lung function and oxygen exchange. * Complete pulmonary function tests (PFTs), 6-minute walk tests (6MWT), and echocardiograms at the beginning and end of the study. * Be monitored for adverse events, with a phone check-in midway through and after the treatment period.
Phase 2
Recruiting
Duke Asthma Allergy and Airway CenterUnited Therapeutics
Have you considered Stiolto Respimat clinical trials? We made a collection of clinical trials featuring Stiolto Respimat, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security